Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Teva reclassified Anda, its U.S. distribution business, from the United States segment to Other Activities effective January 1, 2026.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Teva reclassified Anda, its U.S. distribution business, from the United States segment to Other Activities effective January 1, 2026
- Segment disclosures in the 2025 Form 10-K were recast to align with Teva’s Pivot to Growth strategy and internal reporting
- Consolidated balance sheets, income statements, cash flows and equity statements remain unchanged
- Recast data affects reported segment revenue, profitability and reconciliations, requiring revised comparisons across periods
- Exhibit 99.1 updates business, MD&A and segment-note disclosures for investor analysis
Item EX-99.1 · Exhibit EX-99.1
- Historical segment reporting recast effective January 1, 2026, moving U.S. distribution business Anda into Other Activities
- United States segment now excludes Anda, sharpening visibility into regional pharmaceutical performance and biopharmaceutical growth engines
- Filing is not a financial restatement, with no changes to consolidated balance sheets, income statements or cash flows
- Investors should adjust historical segment comparisons and review 2026 Form 10-Q disclosures for comparability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.